{"id":469515,"date":"2025-05-15T00:00:00","date_gmt":"2025-05-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0016-biopharma-wet-age-related-macular-degeneration-epidemiology-epidemiology-dashboard\/"},"modified":"2026-04-29T23:11:08","modified_gmt":"2026-04-29T23:11:08","slug":"epidop0016-biopharma-wet-age-related-macular-degeneration-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0016-biopharma-wet-age-related-macular-degeneration-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Wet Age-related Macular Degeneration &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of wet age-related macular degeneration (<abbr title=\"age-related macular degeneration\">AMD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> prevalent cases for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>All forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> and the number of new diagnoses of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>?<\/li>\n<li>Of all people diagnosed with wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>, how many in each country in the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total mixed prevalent cases of <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed and undiagnosed prevalent cases of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed drug-treated and non-drug-treated prevalent cases of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-469515","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469515\/revisions"}],"predecessor-version":[{"id":469870,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/469515\/revisions\/469870"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=469515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}